Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.39 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19799069 | 0.80 | PKM (0.39) | HTR2AMTNR1ANQO1PKMTSHR | |
| SCHEMBL4593009 | 0.79 | HTR2C (0.57) | HTR2AMTNR1ANQO1PKMTSHR | |
| SCHEMBL30449882 | 0.79 | HTR2A (0.58) | HTR2AMTNR1AHTR2CHTR2BMTNR1B | |
| SCHEMBL989652 | 0.79 | HTR2A (0.58) | HTR2AMTNR1AHTR2CHTR2BMTNR1B | |
| SCHEMBL28070559 | 0.79 | HTR2A (0.58) | HTR2AMTNR1AHTR2CHTR2BMTNR1B | |
| SCHEMBL28852792 | 0.77 | HTR2A (0.53) | HTR2AMTNR1AHTR2CHTR2BMTNR1B | |
| SCHEMBL3009652 | 0.77 | MEN1 (0.46) | NQO1CYP1A2CYP2A6HSD17B10L3MBTL1 | |
| SCHEMBL4592773 | 0.77 | HTR2C (0.58) | HTR2AMTNR1APKMTSHRHTR2C | |
| SCHEMBL5179342 | 0.77 | PDE10A (0.50) | HTR2ANQO1CYP1A2 | |
| SCHEMBL29175430 | 0.76 | APLNR (0.41) | HTR2ANQO1PKMCSNK2A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1900723-A1 | New naphthalene derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2008-03-19 | — | — | EP | disclosed |
| US-20080004348-A1 | Naphthalene compounds | LES LABORATOIRES SERVIER (FR) | 2008-01-03 | — | — | US | disclosed |
| WO-2008000969-A1 | NOVEL NAPHTHALENIC DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004348-A1 | Naphthalene compounds | MTNR1A, MTNR1B, CNR1 | HTR2A 120/4885MTNR1A 1/4885NQO1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.